Press release BoxID: 162962 (Evotec AG)
  • Evotec AG
  • Manfred Eigen Campus, Essener Bogen 7
  • 22419 Hamburg
  • Contact person
  • Anne Hennecke
  • +49 (40) 56081-286

Evotec Announces Financial Results for 2007

(PresseBox) (Hamburg, Germany | Oxford, UK, ) Evotec AG (Frankfurt Stock Exchange: EVT) today reported financial results according to IFRS for the year ended December 31, 2007.

Financial results for the year were driven by strong progress in the Company's clinical pipeline and four major corporate transactions, the acquisition of Neuro3d, the sale of Evotec Technologies (ET), the sale of the Chemical Development Business (CPD) and the proposed acquisition of Renovis. Including the now discontinued activities, the company achieved revenues of 54.4m EUR (2006: 84.7m EUR) and a net loss of 11.2m EUR (2006: 27.7m EUR). While 2006 included both, ET and CPD for the full year, in 2007, ET was not included anymore and CPD only for eleven months.

In light of the Company's recent divestments, the remainder of this release focuses on the financials of the continuing business of Evotec (referred to as the 'continuing business'). In its continuing business the Company achieved revenues of 32.9m EUR and had total cash and investments of 93.7m EUR respectively, meeting its guidance for 2007 of 30-35m EUR of revenues and 93-98m EUR of cash.

2007 Highlights:

Completion of the corporate development plan:
- 18.9m EUR through the acquisition of Neuro3D, S.A. received
- Evotec Technologies sold to PerkinElmer for 23.9m EUR
- Chemical Development Business sold to Aptuit for 42.5m EUR
- Library business transferred to joint venture with RSIL, India
- Agreement to acquire Renovis, Inc., subject to Renovis stockholder approval

CNS pipeline reached significant value inflection points:
- Positive data from two Phase II trials evaluating EVT 201 strengthening confidence in EVT 201's potential advantages over competitive insomnia therapies
- Phase I safety data for EVT 302 revealed good tolerance up to the highest doses of the potential smoking cessation drug; Phase II initiated (post period-end)
- EVT 101 expected to start Phase II proof-of-concept studies in 2008
- Advanced pipeline including several preclinical programs

Evotec Group revenues from the continuing business in 2007 were 32.9m EUR. The decrease of 19% compared to the previous year (2006: 40.6m EUR) resulted mainly from three effects:

1. Almost half of the effect was due to the delay in receipt of milestone payments, which are now expected to be received in 2008.
2. Library synthesis revenues declined by 5.7 m EUR (86%) following the successful completion of the multi-year collaboration with Merck & Co. at the end of 2006 and the transfer of this business into the joint venture with RSIL in October 2007.
3. Further pressure came from adverse exchange rates.

Adjusting for these factors, revenues of the ongoing business would have grown by 9%.

In 2007, net loss of the continuing business increased to 48.1m EUR(2006: 29.0m EUR) and the operating loss amounted to 58.1m EUR (2006: 34.5m EUR), resulting mainly from the Company's increased investments in research and development programs as well as lower gross profit and impairment. Total R&D expenses increased by 22% to EUR 37.0m (2006: 30.3m EUR), due primarily to the sizable clinical development programs for EVT 201, EVT 302 and the EVT 100 family. SG&A costs increased to 17.8m EUR (2006: 15.0m EUR) mainly as a result of the costs related to corporate transactions as well as increased investment in Business Development and licensing resources.

Evotec reported higher amortization and impairment in 2007 mainly as a consequence of focusing its operations increasingly on proprietary research. In total, impairment charges and regular amortization amounted to 11.1m EUR in 2007, compared to 2.7m EUR in 2006. This increase primarily results from an impairment charge of 5.8m EUR against the carrying value of the goodwill attributable to the Oxford-based laboratory operations, plus a further impairment charge of 3.2m EUR related to earlier discovery projects acquired with Evotec Neurosciences that have been discontinued for strategic prioritization reasons.

On December 31, 2007 Evotec held cash and investments of 93.7m EUR compared to 78.7m EUR at the end of 2006.

"The last year has seen great change at Evotec. We implemented our transformation to a drug development company and thereby, enhanced the Company's potential value creation for our shareholders. In addition, our pipeline is maturing. Two Phase II compounds are being readied for partnering while another compound, close to Phase II, will soon enter trials designed to produce key proof-of-concept data. Finally, several advanced preclinical programs are approaching the clinic. Through the recent divestments of non-core businesses we have increased our liquidity to 94m which is a very solid position to further develop our pipeline," said Jörn Aldag, President & CEO of Evotec AG. "The future is strong for Evotec. The acquisition of Renovis will create a leading drug development company, with a broadened clinical and preclinical pipeline and a combined cash position of pro-forma 141m EUR at the end of 2007. Subject to Renovis stockholder approval, the transaction is expected to close on May 1, 2008 or shortly thereafter. It will give the Company a NASDAQ listing and at the same time, access to the largest biotech investment community in the world."

Financial Guidance

Evotec's financial objectives in this outlook section are those of the combined new Evotec Group based on the assumption that the merger with Renovis will close on May 1, 2008 or shortly thereafter.

In 2008, total Group revenues before out-licensing income are expected to reach 34m EUR to 36m EUR. These assumptions are based on the current order book, expected new contracts and contract extensions as well as, to a lesser extent, the achievement of certain research milestones. Depending on the contribution from out-licensing and additional milestone income, revenues may also be substantially higher.

The operating result before out-licensing income and assuming no 2008 impairment charge, is expected to be in the approximate range of 2007 and in the event of a successful out-licensing may significantly outperform 2007. Evotec continues to invest in research & development (R&D). The Company expects R&D expenses before employee stock compensation to amount to 46 to 51 m in 2008. The increase is mainly driven by progress in the clinical pipeline and the Renovis acquisition.

Liquidity at the end of 2008, after the merger with Renovis, is targeted to exceed 85m excluding out-licensing payments. Assuming the Company's ambitious portfolio development goals and assuming no major out-licensing event, the cash position is currently expected to be sufficient to fund Evotec's development programs over the next three years.

Webcast / Conference Call

Evotec is going to broadcast today's analyst and press conference in Frankfurt starting at 10.30 am CET (09.30 am GMT/05.30 am EDT) live on the internet. The presentation will be held in English.

To join the audio webcast and to access the presentation slides you will find a link on our home page shortly before the event.

For those who prefer to listen to the presentation via phone, please dial:

From Europe: +49.(0)69.5007 1308 (Germany); +44.(0)20.7806 1956 (UK)

From the US: +1.718.354 1389; Access Code: 4484272

A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialing +49.(0)69.22222 0418 (Germany) or +44.(0)20.7806 1970 (UK) and in the US by +1.718.354 1112. The access code is 4484272#. The on-demand version of the webcast will be available on our website: - Investors - Financial Reports.

Link to the Consolidated Financial Statements 2007 of Evotec:

Additional Information

We have filed a Registration Statement on Form F-4 with the Securities and Exchange Commission in connection with the proposed merger. Evotec and Renovis expect to mail a joint proxy statement/prospectus, which will form part of the Registration Statement on Form F-4, to shareholders of Renovis in connection with the proposed merger. This document will contain important information about the merger and should be read before any decision is made with respect to the merger. Investors and stockholders will be able to obtain free copies of this document and any other documents filed or furnished by Evotec or Renovis through the website maintained by the Securities and Exchange Commission at Free copies of these documents may also be obtained from Evotec, by directing a request to Evotec's Investor Relations department at Schnackenburgallee 114, 22525 Hamburg, Germany, or from Renovis, by directing a request to Renovis' Investor Relations department at Two Corporate Drive, South San Francisco, California 94080. You may also read and copy any reports, statements or other information filed or furnished by Evotec or Renovis at the SEC's Public Reference Room at Station Place, 100 F Street, N.E., Washington, D.C. 20549. You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference Room.